These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 21930880)

  • 1. Model-based approach for optimization of atazanavir dose recommendations for HIV-infected pediatric patients.
    Hong Y; Kowalski KG; Zhang J; Zhu L; Horga M; Bertz R; Pfister M; Roy A
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5746-52. PubMed ID: 21930880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies.
    Schipani A; Dickinson L; Boffito M; Austin R; Owen A; Back D; Khoo S; Davies G
    J Acquir Immune Defic Syndr; 2013 Jan; 62(1):60-6. PubMed ID: 23011396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents.
    Foissac F; Blanche S; Dollfus C; Hirt D; Firtion G; Laurent C; Treluyer JM; Urien S
    Br J Clin Pharmacol; 2011 Dec; 72(6):940-7. PubMed ID: 21649692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen.
    von Hentig N; Müller A; Rottmann C; Wolf T; Lutz T; Klauke S; Kurowski M; Oertel B; Dauer B; Harder S; Staszewski S
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1431-9. PubMed ID: 17296738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical approach to HIV protease inhibitor atazanavir for bioavailability enhancement based on solid dispersion system.
    Fukushima K; Terasaka S; Haraya K; Kodera S; Seki Y; Wada A; Ito Y; Shibata N; Sugioka N; Takada K
    Biol Pharm Bull; 2007 Apr; 30(4):733-8. PubMed ID: 17409512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection.
    Colombo S; Buclin T; Cavassini M; Décosterd LA; Telenti A; Biollaz J; Csajka C
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3801-8. PubMed ID: 16940065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.
    Pham PA; Flexner C; Parsons T; Vasist L; Fuchs E; Carson K; Agarwala S; Barditch-Crovo P
    J Acquir Immune Defic Syndr; 2007 Jun; 45(2):201-5. PubMed ID: 17414932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir.
    Gianotti N; Seminari E; Guffanti M; Boeri E; Villani P; Regazzi M; Bigoloni A; Schira G; Tiberi S; Fusetti G; Lazzarin A; Castagna A
    New Microbiol; 2005 Apr; 28(2):119-25. PubMed ID: 16035256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
    Squires KE; Young B; Dejesus E; Bellos N; Murphy D; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
    AIDS; 2010 Aug; 24(13):2019-27. PubMed ID: 20613461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women.
    Conradie F; Zorrilla C; Josipovic D; Botes M; Osiyemi O; Vandeloise E; Eley T; Child M; Bertz R; Hu W; Wirtz V; McGrath D
    HIV Med; 2011 Oct; 12(9):570-9. PubMed ID: 21569187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy.
    Kreitchmann R; Best BM; Wang J; Stek A; Caparelli E; Watts DH; Smith E; Shapiro DE; Rossi S; Burchett SK; Hawkins E; Byroads M; Cressey TR; Mirochnick M
    J Acquir Immune Defic Syndr; 2013 May; 63(1):59-66. PubMed ID: 23392467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and Pharmacodynamics of Atazanavir in HIV-1-Infected Children Treated With Atazanavir Powder and Ritonavir: Combined Analysis of the PRINCE-1 and -2 Studies.
    Sevinsky H; Zaru L; Wang R; Xu X; Pikora C; Correll TA; Eley T
    Pediatr Infect Dis J; 2018 Jun; 37(6):e157-e165. PubMed ID: 29206748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation.
    Winston A; Mallon PW; Satchell C; MacRae K; Williams KM; Schutz M; Law M; Cooper DA; Emery S
    Clin Infect Dis; 2007 Jun; 44(11):1475-83. PubMed ID: 17479946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of atazanavir/ritonavir among HIV-infected Thai children concomitantly taking tenofovir disoproxil fumarate.
    Bunupuradah T; Techasaensiri C; Keadpudsa S; Thammajaruk N; Srimuan A; Sahakijpicharn T; Prasitsuebsai W; Ananworanich J; Puthanakit T;
    Pediatr Infect Dis J; 2014 Dec; 33(12):e316-9. PubMed ID: 24983717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
    Le Tiec C; Barrail A; Goujard C; Taburet AM
    Clin Pharmacokinet; 2005; 44(10):1035-50. PubMed ID: 16176117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients.
    Ma Q; Gelbard HA; Maggirwar SB; Dewhurst S; Gendelman HE; Peterson DR; DiFrancesco R; Hochreiter JS; Morse GD; Schifitto G
    J Neurovirol; 2013 Jun; 19(3):254-60. PubMed ID: 23737347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents.
    Kiser JJ; Rutstein RM; Samson P; Graham B; Aldrovandi G; Mofenson LM; Smith E; Schnittman S; Fenton T; Brundage RC; Fletcher CV
    AIDS; 2011 Jul; 25(12):1489-96. PubMed ID: 21610486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
    Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Rightmire A; Sankoh S; Wilber R
    AIDS; 2005 Apr; 19(7):685-94. PubMed ID: 15821394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.
    Moltó J; Santos JR; Valle M; Miranda C; Miranda J; Blanco A; Negredo E; Clotet B
    Ther Drug Monit; 2007 Oct; 29(5):648-51. PubMed ID: 17898658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.
    Colombo S; Buclin T; Franc C; Guignard N; Khonkarly M; Tarr PE; Rochat B; Biollaz J; Telenti A; Decosterd LA; Cavassini M
    Antivir Ther; 2006; 11(1):53-62. PubMed ID: 16518960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.